Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer by Maj-Britt Jensen, Torsten O. Nielsen, John Bartlett, Anne-Vibeke Lænkholm, Lois Shepherd, Bent Ejlertsen

Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

Get full text

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases... by Fiona M Blows, Kristy E Driver, Marjanka K Schmidt, Annegien Broeks, Flora E van Leeuwen, Jelle Wesseling, Maggie C Cheang, Karen Gelmon, Torsten O Nielsen, Carl Blomqvist, Päivi Heikkilä, Tuomas Heikkinen, Heli Nevanlinna, Lars A Akslen, Louis R Bégin, William D Foulkes, Fergus J Couch, Xianshu Wang, Vicky Cafourek, Janet E Olson, Laura Baglietto, Graham G Giles, Gianluca Severi, Catriona A McLean, Melissa C Southey, Emad Rakha, Andrew R Green, Ian O Ellis, Mark E Sherman, Jolanta Lissowska, William F Anderson, Angela Cox, Simon S Cross, Malcolm W R Reed, Elena Provenzano, Sarah-Jane Dawson, Alison M Dunning, Manjeet Humphreys, Douglas F Easton, Montserrat García-Closas, Carlos Caldas, Paul D Pharoah, David Huntsman

Get full text